Inspiratory Muscle Training X CardioBreath App Effects On Vagal Modulation And Pulse Wave Velocity

Vascular Stiffness Clinical Trial

— CardioBreath  

Official title:

Inspiratory Muscle Training X CardioBreath App Effects On Vagal Modulation And Pulse Wave Velocity On Normotensive Postmenopause Women : Randomized Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03672760
• Other study ID #: Cardiology
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 1, 2023
• Est. completion date: December 30, 2024

Study information

• Verified date: March 2023
• Source: Instituto de Cardiologia do Rio Grande do Sul
• Contact: Cláudia Fetter, MSc
• Phone: +5551984516888
• Email: profclaudiafetter[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Existing data points to relevant beneficial effects of respiratory exercises on cardiovascular health, with special regards to decreases on arterial pressure and improves on autonomic and vascular profiles, though mechanistics of such results have not yet been cleared. Among the available ways to perform respiratory exercises, there is the highly recommended Inspiratory Muscle Training (IMT) and slow breathing exercises like Yoga pranayamas. Lately, the development of new technologies has allowed the use of Apps to perform respiratory exercises. This study will be take the just developed CardioBreath®App to validate it as a tool to perform respiratory exercises. Therefore, it will be compared to IMT on cardiac vagal modulation and pulse wave velocity on normotensive post menopause women.

Description:

Menopause years represent an increasing risk for hypertension and autonomic nervous system (ANS) and vascular imbalance. Existing data point to beneficial effects of respiratory exercises either on ANS and light on therapeutic relevance of these kind of exercises on prevention and treatment of cardiovascular and pulmonary diseases. However, few data is available about the effects of respiratory exercises on both vascular function and interactions with ANS. Besides that, recommendations of slower respiratory rates are associated to healthier physical and psychological states. Among available techniques to perform breathing exercises, most referenced are Inspiratory Muscle Training (IMT) and Yoga based slow breathing (pranayamas). New technologies have allowed the development of Apps which aim to ease the possibilities of exercising breathing. IMT uses a mouth device for pressure adjustment and presents a variety e training forms including combinations of intensity and volume through loads adjustment. It aims the enhancement of respiratory muscles strength and endurance. CardioBreath®App has been developed by experienced physical education and yoga professional based on individual prescription of respiratory rates to workout through voice and image guidance of both posture and breathing technique. The performance might be followed through a progression map. It´s available in portuguese language for Android and Ios, has been submitted to Brazilian Trend Marks Institute (INPI) which has not shown opposition to the registration. It´s a randomized clinical trial recruiting normotensive post menopause women. Eligible participants will be assessed by Finometer for blood pressure and heart rate variability as measures for autonomic outcomes. Data analysis of these data will be processed by CardioSeries software through Fourier fast transform (FFT) in order to generate vagal and sympathetic values. For pulse wave velocity and central arterial pressure the participants will be assessed by Complior Analyser. The participants will be randomized into 3 intervention groups as follows: IMT, IMT placebo and CardioBreath®App. The intervention will long five weeks. The exercises will be performed at home for five days/ week during 10 minutes and will be registered by audio for whatsapp (IMT) and "Progress" graphics (CardioBreath®App) Once a week they will visit the laboratory set to adjust loads (IMT) and respiratory rates in CardioBreath®App groups, respectively. After five weeks the participants will be re-evaluated for all outcomes described above. Data analysis will be provided by ANOVA of two repeated measures and Bonferroni post hoc. All data will be presented in mean +- standard deviation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 24
• Est. completion date: December 30, 2024
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 45 Years to 65 Years

Eligibility

Inclusion Criteria:

• Follicle Stimulating Hormone (FSH)>35mui/ml
• minimum 12 months amenorrhea
• sedentary life style (less than 150 minutes per week of exercise)

Exclusion Criteria:

• Hypertension
• Diabetes
• Obesity
• Use of Betablockers
• recent cardiovascular events or surgery
• renal alterations
• respiratory and/or motor pathologies
• smoking
• BMI>29,9

Related Conditions & MeSH terms

• Autonomic Imbalance
• Postmenopausal Disorder
• Respiratory Aspiration
• Vascular Stiffness

Intervention

Device:
• CardioBreathApp
Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance
• IMT PowerBreath
Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure
• IMT PowerBreath Placebo
Inspiratory Muscle Training (IMT) without load

Locations

Country	Name	City	State
Brazil	Cardiology Institute of Rio Grande do Sul	Pôrto Alegre	Rio Grande Do Sul

Sponsors (1)

Lead Sponsor	Collaborator
Instituto de Cardiologia do Rio Grande do Sul

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Respiratory rate by Pneumotrace respiratory belt	Respiratory rate in cycles per minute (CPM)	30 minutes along with Finometer
Other	Diaphragm Thickness by ultrasound	Increase diaphragm thickness (mm)	5 minutes
Primary	Cardiovascular autonomic control by heart rate variability(HRV)	High Frequency (HF) component of HRV (ms2 = squared milliseconds) as measure of vagal modulation	30 minutes
Secondary	Carotid -femoral pulse wave velocity (Complior)	Reduction of carotid -femoral pulse wave velocity (m/s)	10 minutes